$PFSA

HRT FINANCIAL LP purchased $5K of PFSA

HRT FINANCIAL LP purchased 5,585 shares of Profusa, Inc. (PFSA) at $0.96 on 2026-08-12.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Aug 14, 2026, 4:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 4:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFSA
Bullish
medium confidence
Mentioned
$PFSA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFSABullishLow
01

Why it matters

The newest fact is the specific open-market purchase size, price, and post-transaction holdings (116,609 shares). This can slightly influence sentiment but lacks accompanying company-specific fundamentals.

02

Market read

Traders may note incremental bullish sentiment from a 10% owner purchase, but the transaction size is small and unlikely to be a standalone driver.

03

What to watch

The filing does not state intent, timing constraints, or whether the purchase is part of a broader accumulation program; also, the absence of a 10b5-1 plan does not by itself confirm conviction.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-14, purchase dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Profusa, Inc. (PFSA) by HRT Financial LP, identified as a 10% owner.

Company-level read

Ticker impact

$PFSABullishMedium confidence
Context

Profusa, Inc. disclosed via Form 4 that HRT Financial LP bought 5,585 shares of PFSA at $0.9640 on 2026-08-12.

Expected impact

Likely limited near-term impact; any effect would be incremental sentiment rather than a re-rating catalyst.

Evidence & confidence

The filing is primary-source and time-stamped, but the disclosed dollar value ($5,383.94) is small relative to typical market-moving thresholds, and there is no accompanying guidance, deal, or operational change.

Market effects

No sector-wide implications; this is a single-issuer insider/owner transaction disclosure.

None indicated.

None indicated.

Counterpoint

Owner buying on a Form 4 can reflect liquidity management or routine rebalancing rather than a bullish view on fundamentals.

Key entities

  • Profusa, Inc.

    Subject of the Form 4 disclosure, ticker PFSA.

  • HRT Financial LP

    Reporter of the Form 4 transaction, purchased 5,585 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFSALow

Profusa, Inc. (PFSA): Results of Operations and Financial Condition

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.